 MELBOURNE, Australia, March 31, 2021 GLOBE NEWSWIRE -- Opthea Limited ASX:OPT; Nasdaq:OPT, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces that it has received an initial Pediatric Study Plan iPSP waiver from the US Food and Drug Administration FDA for OPT-302, the Companys lead product candidate currently in Phase 3 clinical development for the treatment of neovascular wet age-related macular degeneration. 